Brii Biosciences - Breakthrough innovation & insight

Title

Therapy Area
Amubarvimab/Romlusevimab: First Approval
Drugs

August 23, 2022
Safety and Antiviral Activity of Two Monthly Administration of BRII-835 (VIR-2218), an X-Targeting RNAi Therapeutic, in Chinese Patients with Chronic HBV Infection
Presentation at the 2022 APASL conference

March 31, 2022

Hepatitis B
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
JHEP Reports

September 07, 2021

Hepatitis B
Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
medRxiv

July 23, 2021

COVID-19